Established in 2021 with 25 million RMB in capital, INNOBIOMAX operates as a wholly-owned subsidiary of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., a member company of the renowned Yangshengtang Group. We specialize in developing and manufacturing high-performance bioactive materials and cutting-edge diagnostic components for global IVD manufacturers. By combining our parent company's extensive biopharmaceutical expertise with focused innovation in diagnostic technologies, we're committed to enabling more accessible, reliable diagnostic solutions that ultimately improve patient outcomes worldwide.

With established expression systems including E. coli, CHO cells, and insect cells, coupled with comprehensive antibody development platforms (encompassing mouse/rabbit monoclonal antibodies and polyclonal antibodies), the company has mastered critical quality parameters for bioactive materials - achieving exceptional control over sensitivity, specificity, stability, and batch-to-batch consistency. Our industrialized production capabilities now span nearly 300 high-performance bioactive products across 10+ diagnostic categories, from infectious diseases and tumor markers to cardiac, hormonal, and nuclease testing - positioning us as a vertically-integrated solutions provider for the global IVD industry.